- Home
- ELMD vs XOMAP Comparison
ELMD vs XOMAP Comparison
Compare ELMD & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELMD
- XOMAP
- Stock Information
- Founded
- ELMD 1992
- XOMAP N/A
- Country
- ELMD United States
- XOMAP United States
- Employees
- ELMD N/A
- XOMAP 13
- Industry
- ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- ELMD Health Care
- XOMAP Health Care
- Exchange
- ELMD Nasdaq
- XOMAP Nasdaq
- Market Cap
- ELMD N/A
- XOMAP N/A
- IPO Year
- ELMD 2010
- XOMAP N/A
- Fundamental
- Price
- ELMD $29.72
- XOMAP $25.78
- Analyst Decision
- ELMD
- XOMAP
- Analyst Count
- ELMD 0
- XOMAP 0
- Target Price
- ELMD N/A
- XOMAP N/A
- AVG Volume (30 Days)
- ELMD 114.1K
- XOMAP N/A
- Earning Date
- ELMD 11-12-2024
- XOMAP N/A
- Dividend Yield
- ELMD N/A
- XOMAP N/A
- EPS Growth
- ELMD 94.54
- XOMAP N/A
- EPS
- ELMD 0.72
- XOMAP N/A
- Revenue
- ELMD $57,060,000.00
- XOMAP N/A
- Revenue This Year
- ELMD $14.27
- XOMAP N/A
- Revenue Next Year
- ELMD N/A
- XOMAP N/A
- P/E Ratio
- ELMD $41.47
- XOMAP N/A
- Revenue Growth
- ELMD 14.73
- XOMAP N/A
- 52 Week Low
- ELMD $9.81
- XOMAP N/A
- 52 Week High
- ELMD $30.00
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- ELMD 72.13
- XOMAP 46.03
- Support Level
- ELMD $27.77
- XOMAP $25.69
- Resistance Level
- ELMD $29.62
- XOMAP $25.98
- Average True Range (ATR)
- ELMD 1.55
- XOMAP 0.13
- MACD
- ELMD 0.23
- XOMAP -0.03
- Stochastic Oscillator
- ELMD 96.11
- XOMAP 16.11
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.